Fmr LLC Buys 1,767,714 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

FMR LLC increased its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 29.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,822,275 shares of the biotechnology company's stock after acquiring an additional 1,767,714 shares during the period. FMR LLC owned about 13.86% of Astria Therapeutics worth $86,123,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ATXS. Vanguard Group Inc. lifted its position in Astria Therapeutics by 23.4% in the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company's stock valued at $35,693,000 after purchasing an additional 480,184 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Astria Therapeutics during the 1st quarter valued at $200,000. Bank of New York Mellon Corp boosted its position in Astria Therapeutics by 6.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company's stock valued at $1,266,000 after buying an additional 8,965 shares during the period. Panagora Asset Management Inc. grew its holdings in Astria Therapeutics by 104.7% in the 2nd quarter. Panagora Asset Management Inc. now owns 30,926 shares of the biotechnology company's stock worth $281,000 after acquiring an additional 15,816 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Astria Therapeutics by 4.1% in the second quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company's stock valued at $595,000 after acquiring an additional 2,556 shares during the period. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on ATXS shares. Wedbush reiterated an "outperform" rating and set a $22.00 target price on shares of Astria Therapeutics in a report on Tuesday, August 13th. Oppenheimer boosted their target price on Astria Therapeutics from $26.00 to $28.00 and gave the company an "outperform" rating in a research note on Thursday, November 14th. Evercore ISI raised Astria Therapeutics to a "strong-buy" rating in a research note on Wednesday, August 14th. Finally, HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $25.60.

Astria Therapeutics Stock Performance

Shares of NASDAQ ATXS traded up $0.60 during mid-day trading on Friday, hitting $10.35. 147,298 shares of the stock traded hands, compared to its average volume of 598,604. The stock has a fifty day moving average price of $10.98 and a 200-day moving average price of $10.64. The company has a market cap of $584.05 million, a price-to-earnings ratio of -4.67 and a beta of 0.67. Astria Therapeutics, Inc. has a 52 week low of $4.97 and a 52 week high of $16.90.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.